A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

Trial Profile

A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Mar 2018 Planned End Date changed from 1 Jul 2021 to 1 Dec 2021.
    • 05 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
    • 06 Sep 2017 According to trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, ten patients have been enrolled as of 7 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top